Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bicalutamide

FDA-approved product (tablet, oral), marketed as Bicalutamide, Casodex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Bicalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bicalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bicalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

    NCT02582749 · start 2016-04

    Registered record
    Registry ID
    NCT02582749
    Conditions
    Prostate Cancer; Bone Metastases; Prostate Neoplasms
    Interventions
    LHRH agonist/antagonist; Bicalutamide; Radium-223 dichloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-04
    Completion
    2017-09-14
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Bone Metastases; Prostate Neoplasms
    InterventionLHRH agonist/antagonist; Bicalutamide; Radium-223 dichloride
    PhasePhase 2
    Registry statusTerminated

  • Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer

    NCT02615223 · start 2015-11

    Registered record
    Registry ID
    NCT02615223
    Conditions
    Stage IV Prostate Cancer
    Interventions
    cryoablation; Bicalutamide; luteinizing-hormone releasing-hormone (LHRH) agonist
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2018-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IV Prostate Cancer
    Interventioncryoablation; Bicalutamide; luteinizing-hormone releasing-hormone (LHRH) agonist
    PhaseNot applicable
    Registry statusUnknown

  • AR-inhibitor Bicalutamide in Treating Patients With TNBC

    NCT02353988 · start 2015-01

    Registered record
    Registry ID
    NCT02353988
    Conditions
    Breast Neoplasms
    Interventions
    Bicalutamide; Physician's Choice
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2017-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionBicalutamide; Physician's Choice
    PhasePhase 2
    Registry statusUnknown

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance

    NCT02146937 · start 2014-03

    Registered record
    Registry ID
    NCT02146937
    Conditions
    Detectable Prostate Nodules
    Interventions
    Bicalutamide plus Finasteride- Combination therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2014-03
    Completion
    2015-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDetectable Prostate Nodules
    InterventionBicalutamide plus Finasteride- Combination therapy
    PhasePhase 2
    Registry statusWithdrawn

  • Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

    NCT02064036 · start 2013-06-06

    Registered record
    Registry ID
    NCT02064036
    Conditions
    Adenocarcinoma of the Prostate
    Interventions
    Stereotactic Radiosurgical Boost; Casodex; Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06-06
    Completion
    2021-10-29
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate
    InterventionStereotactic Radiosurgical Boost; Casodex; Leuprolide
    PhasePhase 1
    Registry statusCompleted

  • Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

    NCT00669162 · start 2012-08

    Registered record
    Registry ID
    NCT00669162
    Conditions
    Prostate Cancer
    Interventions
    Docetaxel; Radiation Therapy; Casodex and Zoladex (or Lupron)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2017-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDocetaxel; Radiation Therapy; Casodex and Zoladex (or Lupron)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects

    NCT01415778 · start 2011-08

    Registered record
    Registry ID
    NCT01415778
    Conditions
    Healthy
    Interventions
    ICI176,334-1; Casodex 80 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionICI176,334-1; Casodex 80 mg tablet
    PhasePhase 1
    Registry statusCompleted

  • A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

    NCT01288911 · start 2011-03-22

    Registered record
    Registry ID
    NCT01288911
    Conditions
    Prostatic Neoplasms
    Interventions
    enzalutamide; bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-03-22
    Completion
    2017-11-08
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    Interventionenzalutamide; bicalutamide
    PhasePhase 2
    Registry statusCompleted

  • Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

    NCT01342367 · start 2010-12-17

    Registered record
    Registry ID
    NCT01342367
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide; Dutasteride; Finasteride; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2010-12-17
    Completion
    2026-02
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide; Dutasteride; Finasteride; Radiation
    PhaseNot applicable
    Registry statusActive not recruiting

  • Oral Mucosal Absorption Study of Bicalutamide New Formulation

    NCT01416883 · start 2010-07

    Registered record
    Registry ID
    NCT01416883
    Conditions
    Healthy
    Interventions
    ICI176,334-1
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2010-07
    Completion
    2010-08
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionICI176,334-1
    PhasePhase 1
    Registry statusTerminated

  • Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

    NCT00833248 · start 2009-04

    Registered record
    Registry ID
    NCT00833248
    Conditions
    Prostate Cancer
    Interventions
    Degarelix; Goserelin; Bicalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2011-09
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDegarelix; Goserelin; Bicalutamide
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide

    NCT00871585 · start 2009-03

    Registered record
    Registry ID
    NCT00871585
    Conditions
    Advanced Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-01
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Prostate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

    NCT00943956 · start 2009-01

    Registered record
    Registry ID
    NCT00943956
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; everolimus; leuprolide acetate; external beam radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2012-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; everolimus; leuprolide acetate; external beam radiation therapy
    PhasePhase 1
    Registry statusCompleted

  • Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

    NCT00814788 · start 2008-12

    Registered record
    Registry ID
    NCT00814788
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2016-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide; Everolimus
    PhasePhase 2
    Registry statusCompleted